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Background: Migraine is associated with many debilitating symptoms that affect daily functioning. My Migraine
Voice is a large global cross-sectional study aimed at understanding the full burden and impact of migraine directly
from patients suffering from ≥4 monthly migraine days (MMDs) with a history of prophylactic treatment failure.
Methods: This study was conducted worldwide (31 countries across North and South Americas, Europe, the Middle
East and Northern Africa, and the Asia-Pacific region) using an online survey administered to adults with migraine
who reported ≥4 MMDs in the 3 months preceding survey administration, with pre-specified criteria of 90% having
used preventive migraine treatment (80% with history of ≥1 treatment failure). Prophylactic treatment failure was
defined as a reported change in preventive medication by individuals with migraine for any reason, at least once.
Results: In total, 11,266 individuals participated in the survey. Seventy-four percent of the participants reported
spending time in darkness/isolation due to migraine (average: 19 h/month). While 85% of all respondents reported
negative aspects of living with migraine (feeling helpless, depressed, not understood), sleeping difficulties (83%),
and fear of the next attack (55%), 57% shared ≥1 positive aspect (learning to cope, becoming a stronger person).
Forty-nine percent reported feeling limited in daily activities throughout all migraine phases. Migraine impact on
professional, private, or social domains was reported by 87% of respondents (51% in all domains). In the previous
12 months, 38% of respondents had visited the emergency department (average: 3.3 visits), whereas 23% stayed in
hospital overnight (average: 3.2 nights) due to migraine.
Conclusions: The burden of migraine is substantial among this cohort of individuals with at least 4 migraine days
per month and for whom at least 1 preventive migraine treatment had failed. Interestingly, respondents reported
some positive aspects in their migraine journey; the greater resilience and strength brought on by coping with
migraine suggests that if future treatments could address existing unmet needs, these individuals with migraine will
be able to maximize their contribution to society.
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Migraine is a painful, debilitating neurological disease,
which consistently ranks among the top 10 leading
causes of years lived with disability (YLD) worldwide
[1, 2]. It is currently the first-leading cause of YLD
among individuals under 50 years old [3].
The impact of migraine on all domains of life con-
tributes to the complexity of adequately capturing its
true wide-ranging burden from the perspective of
people with migraine, particularly those experiencing a
relatively high frequency of migraine attacks and with
unmet treatment needs. Multiple previous studies and
surveys described various manifestations of the burden
of migraine, such as the American Migraine Prevalence
and Prevention (AMPP) study, the International Bur-
den of Migraine Study (IBMS), the Chronic Migraine
Epidemiology and Outcomes (CaMEO) study, the
Eurolight project, and the Global Burden of Disease
(GBD) study [4–10]. However, the current understand-
ing of migraine burden among individuals with the
highest unmet needs, specifically those experiencing
≥4 monthly migraine days (MMDs) and prior prophy-
laxis failure, is limited. This particular subgroup is of
interest since new preventive migraine therapies have
demonstrated efficacy and safety in this population.
Furthermore, understanding the burden of disease in
individuals with ≥4 MMDs is very important to enable
physicians and/or others involved in migraine manage-
ment to make well-informed decisions on appropriate
preventive migraine care for these people. Specifically,
no detailed assessment of the current treatment path-
way, impact on work productivity, or burden associ-
ated with premonitory and postdromal phases of
migraine is available in individuals experiencing ≥4
MMDs who have had previous prophylactic treatments
that failed and continue to experience frequent migraines.
A qualitative study was conducted using online
bulletin boards (OBBs) to identify the key issues expe-
rienced by people living with migraine prior to the
present global study [11, 12]. OBBs are a qualitative data
collection method that allow anonymous participation
across varied geographic locations, customization of ques-
tions, and interactions and answers in local languages to
facilitate and enhance data quality; qualitative data from
OBBs were used to inform the My Migraine Voice study.
The OBB study highlighted the challenges and important
impacts of migraine on many aspects of the daily lives of
individuals with migraine. This permitted the substantial
functional and emotional burden associated with migraine
to be described by affected individuals in their own words
[11, 12]. People with migraine reported facing significant
challenges in pursuing daily activities or work and difficul-
ties with coping mechanisms. The negative impact of mi-
graine also extended to caregivers, most of them beingtorn between commitment, self-sacrifice, and resentment
in relation to their responsibilities toward the person with
migraine for whom they were providing care [11, 12].
Building on this first initiative, the quantitative My
Migraine Voice study was undertaken on a much larger
and comprehensive scale via an online survey to fur-
ther understand views of people with migraine and its
worldwide impact across 31 countries. The objectives
of My Migraine Voice were to assess migraine charac-
teristics and describe the current real-world burden
and impact of living with migraine from clinical, per-
sonal, and economic perspectives among adults with
migraine experiencing ≥4 MMDs.
Methods
Study design and participants
This was a large, cross-sectional, multi-country online
survey of adult participants (≥18 years of age) with
migraine. Screening questions to determine eligibility
included a description of migraine based on the Inter-
national Classification of Headache Disorders 3rd
edition (ICHD-3) criteria followed by a series of mi-
graine symptom and characteristic questions to qual-
ify that participants were experiencing migraine.
Participants could also record whether they had re-
ceived a medical diagnosis of migraine, although this
was not part of the inclusion criteria. Further, only
those who self-reported experiencing ≥4 MMDs each
month for the previous 3 months were eligible for in-
clusion in the survey.
Prespecified quotas were applied to people reporting
a history of taking a prophylactic medication to pre-
vent their migraine: 90% of participants reported
current or previous use of preventive migraine medica-
tion, of which 80% switched preventive treatment, and
the remaining 10% were preventive treatment-naïve.
Individuals with migraine who reported changing their
preventive medication for any reason at least once
were defined to have had a preventive treatment failure
(TF). The applied quotas were required to ensure that
the occurrence of TF was adequately represented
among study participants, with a substantive propor-
tion of individuals that had a history of ≥2 TFs.
Participants were recruited by means of existing on-
line panels (GfK Health) and support organizations for
people with migraine. Participants’ consent was ob-
tained prior to participation in the survey and those
who completed the survey were compensated with an
incentive in the form of a voucher and aligned with
local standards. Data were collected via Confirmit, an
online platform, and internet surveys were completed
independently by respondents. Data were handled con-
fidentially and anonymity of respondents was main-
tained throughout the study. As such, and due to its
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Survey design and outcomes
The survey drew upon the previous OBB study results.
Details on the methods of the OBB study are published
elsewhere [11, 12]. A steering committee composed of
migraine specialists, a specialized nurse, and patient sup-
port group leaders also informed the methodology and
additional topics of importance. The final survey com-
prised 88 questions and included country-specific ques-
tions tailored to reflect differences in healthcare systems
and available treatments.
Table 1 presents the outcome parameters assessed in
the survey relating to sociodemographic factors, healthTable 1 Parameters Collected in the Survey
Domain Items
Sociodemographic
characteristics
• Age
• Gender
• Income
• Place of living
• Occupation status
• Family status
Health/medical history • Monthly migraine days
• Monthly headache days
• Characteristics of migraine (eg,
symptoms, pain, nausea, aura,
duration)
• Medication history
• Migraine history (eg, time affected
by migraine, diagnosis, time since
diagnosis, engagement with HCPs)
• Family history of migraine and
headache (parents, siblings, children)
• Comorbidities (chronic conditions)
QoL • QoL
• Experience of living with migraine
(eg, fear of migraine attack, ability
to focus, fatigue, feelings of
frustration/hopelessness)
Healthcare utilization • Healthcare utilization (eg,
hospitalizations, ED visits, outpatient
visits, general practitioners,
neurologists, headache centers,
brain scans)
• Treatments for relief of
headache/migraine
• Treatments for prevention of
headache/migraine
• Non-pharmacological management
Impact on daily life • Work status (including changes in
employment due to migraine)
• Daily activities and household
activities
• Work productivity using
WPAI-Migraine
Treatment patterns/ participants’
treatment experience
• Time on treatment
• Treatment satisfaction
• Reason for switching (if any)
ED Emergency department; HCP Healthcare provider; QoL Quality of life; WPAI
Work Productivity and Activity Impairmentand medical history, health-related quality of life, impact
on daily activities, treatment patterns and participants’
treatment experience, and healthcare utilization.
Because of limited published information on the
burden before and after the migraine attack, the sur-
vey included questions on the migraine phases. De-
scriptions of migraine phases were provided to
participants (Table 2).
In addition, a validated questionnaire was included
in the survey to assess the impact of migraine on work
productivity and daily activities among employed re-
spondents. The impact of migraine on work productiv-
ity and regular activities during the past 7 days was
evaluated using the Work Productivity and Activity
Impairment (WPAI) questionnaire and was compared
among treatment -naive, no prior TF, 1 TF, and ≥ 2 TF
patient subgroups.
Data analysis
Data analysis was conducted using IBM SPSS Statis-
tics (version 24) to generate summary statistics on
country and aggregate levels, and Qlikview software
was used for charting. Quality assessment of the data
was performed and included an evaluation of re-
sponse patterns and inconsistencies and an analysis of
answers to open-ended questions. Comparisons of
different subset of participants were completed using
frequencies, means, medians, and standard deviations.
The reported P-values are from the T-student test
when testing differences between averages, and from
the Chi-square test when testing differences between
percentages or proportions.
Results
Worldwide recruitment occurred from September
2017 to February 2018 across 31 countries in North
America (n = 1689) and South America (n = 1438),
Europe (n = 6156), the Middle East and Northern Af-
rica (n = 1111), and the Asia-Pacific region (n = 872),
resulting in the participation of a total of 11,266 indi-
viduals with migraine in My Migraine Voice (Fig. 1).
Per the predefined inclusion criteria, approximately
90% of participants (n = 9856) had taken preventive
medication (past or present) for migraine, and ≥ 80% of
these (n = 7678) had experienced at least 1 or more TF,
which represents 68% of the total survey population (Fig.
1). The majority of participants with a previous treatment
failure were those who had ≥2 TFs (n = 6717; 87% of those
with any TF).
The characteristics of the study participants are sum-
marized in Table 3. Of the total 11,266 participants, a
majority were female, had children, and had a family
history of migraine. The majority of participants were
in either full- (47%) or part-time (12%) paid
Table 2 Description of Migraine Phases
Premonitory Phase (Before the Attack) Headache Phase (The Attack) Postdromal Phase (After the Attack)
Warning phase
Might occur days or hours
before
• Concentration problems
• Irritability
• Repetitive yawning
• Sleep issues
• Food cravings
• Tiredness
Aura
• Sensory disturbances
• Speech disturbances
• Visual disturbances
• Symptoms last up to one
hour
The attack (and accompanying
symptoms)
• Throbbing one-sided headache
• Sickness, nausea
• Sensitive to light, sound
Resolution
• Sleep helps
• Fatigue
• Food intolerance
• Altered mood
• Impaired
concentration
• Less intense pain
Recovery
• Hangover
feeling
• Weak
• Need rest
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(7%). On average, participants had migraine for 11.6
years, but over one-quarter (27%) had it for more than
20 years. The majority of participants (86%) also re-
ported currently having a healthcare professional for
their migraine, most frequently a neurologist or head-
ache specialist (41%) or general practitioner (42%).
Seventy-six percent of survey participants reported
taking medications for acute treatment, which in-
creased to 81% among those with ≥2 TFs. Of the par-
ticipants taking medications for acute treatment, 83%
took these based on a doctor’s prescription and 51%
also took over-the-counter (OTC) medications, indi-
cating that a substantive proportion of respondents
were taking both doctor-prescribed and OTC medica-
tions. Notably, among respondents taking acute treat-
ments, 20% reported using opioids for their migraine.
Overall, study respondents reported having 3.3 other
chronic conditions on average, with anxiety, insomnia/
sleep disorders, and depression being most commonly
reported in all participants, irrespective of whether
they had experienced previous preventive TF.100% of patients have at leas
days each month in the las
(11,266)
About 10%* have not
used preventive 
therapy (1,409)
About 80%* have needed to chang
the preventive therapy (7,678)
How many times have you had to
change your therapy?
1 time (961)
At least 2 times (6,717)
Invited to participa
(598,239)
 D
 D
 E
Fig. 1 The My Migraine Voice Study Population Accrued per Applied CriteriMigraine characteristics
Considering all phases of the migraine attack, survey
participants had on average 9.8 days/month affected by
migraine over the last 3 months. For 44% of respon-
dents, migraine episodes lasted 1 to 2 days or more,
and 19% reported episodes lasting longer than 3 days.
A headache phase duration longer than 1 day was re-
ported by 27% of respondents without any TF com-
pared with 38% of respondents who had ≥2 TFs (P <
0.05) (Table 4). Almost half of respondents (49%) re-
ported feeling limited in completing daily activities
throughout the 3 migraine attack phases (feeling lim-
ited over a total of 10.5 days/month on average). Peak
of limitations occurred during the headache phase as
reported by 71% of respondents vs 75% for those with
≥2 TFs (P < 0.05) who felt very to extremely limited
during the phase. About one-third of respondents also
felt this level of limitation in the premonitory and
postdromal phases (Table 4). Very few respondents re-
ported feeling “no limitation” in each of the migraine
phases (4%, 1%, and 5% in the premonitory, headache,
and postdromal phases, respectively).t 4 migraine
t 3 months
About 90%* have taken at least one
preventive therapy (past or current)
(9,856)
e About 20%* have never
changed their preventive
therapy (2,179)
te 
id not pass screening (425,288)
id not complete questionnaire (124,089)
xcluded to fulfil applied recruitment quotas (37,596)
a. *Predetermined quotas
Table 3 Baseline Characteristics of the My Migraine Voice Population
Total Population
(n = 11,266)
Migraine Individuals
With 1 TF (n = 961)
Migraine Individuals
With ≥2 TFs (n = 6717)
Gender
Female 75% (8396) 77% (735) 73% (1859)
Male 25% (2689) 24% (226) 27% (652)
Age (mean) 39.4 years 39 years 40.2 years
With children (yes) 63% (7098) 58% (557) 67% (4500)
Employed (full time or part-time) 58% (6534) 57% (548) 59% (3963)
Family history of migraine (yes) 54% (6083) 53% (509) 56% (3761)
Time being affected by migraine (mean) 11.6 years 10.9 years 12.2 years
< 1 year 4% (423) 5% (49) 2% (150)
1–5 years 26% (2929) 29% (281) 23% (1537)
6–10 years 21% (2381) 21% (199) 22% (1492)
11–15 years 12% (1350) 10% (96) 13% (852)
16–20 years 10% (1149) 9% (84) 11% (717)
21 years or more 27% (3034) 26% (252) 29% (1969)
Taking acute migraine
medications
76% (8562) 75% (721) 81% (5440)
Average number of self-reported chronic conditions 3.3 3.1 3.4
First most commonly reported: anxiety 27% (3042) 25% (240) 28% (1881)
Second most commonly reported: insomnia/ sleep disorder 24% (2704) 21% (202) 26% (1746)
Third most commonly reported: depression 23% (2591) 22% (211) 25% (1679)
TF Treatment failure
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Although the main symptom of migraine reported by
86% of respondents was a long-lasting headache (from
4 to 72 h), other symptoms such as severe pain either
on one side of the head (75%) or throbbing pain (78%),
light sensitivity (80%), sound sensitivity (75%), and
nausea (74%) were also reported by 74% to 80% of par-
ticipants. On a scale from 0 to 10 (highest level), theTable 4 Characteristics of Migraine Phases
Premonito
Duration of phase
< 4 h 50% (5676
4–24 h 30% (3312
> 24 h 14% (1622
Not experiencing this phase 6% (656)
Proportion of individuals in each preventive treatment group reporting the d
- No failure to migraine preventive treatment 11% (250)
- 1 TF of migraine preventive treatment 11% (103)
- ≥2 TFs of migraine preventive treatment 17% (1114
- P-value: ≥2 failures vs no failure of migraine preventative
treatment
< 0.05
Feeling very to extremely limited during the phase 29% (3047
TF Treatment failureseverity of pain experienced during the last month by
respondents was 7.4 on average, including 57% of
respondents with a higher than average pain severity
(8–10). Notably, overall, 74% of respondents (78% of
those with ≥2 TFs) reported spending long periods of
time in darkness and isolation—an average of 19 h
per month and increasing to 21 h per month in those
with ≥2 TFs. Migraine was also reported to causery Phase, % (N) Headache Phase, % (N) Postdromal Phase, % (N)
) 20% (2280) 30% (3419)
) 45% (5067) 40% (4516)
) 34% (3835) 27% (3006)
1% (84) 3% (325)
uration of this migraine attack phase > 24 h:
27% (599) 20% (436)
29% (282) 23% (218)
) 38% (2539) 31% (2048)
< 0.05 < 0.05
) 71% (8023) 30% (3291)
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(86% for those with ≥2 TFs).
Table 5 summarizes the range of circumstances and
ways in which respondents reported that over the
previous 1 month, migraine had negatively affected
their daily functioning. Notably, in each case, a higher
proportion of respondents with ≥2 TFs reported a
negative impact on daily functioning compared with
the overall participant population. Four out of 5 re-
spondents reported having to cancel plans due to mi-
graine. When asked how they felt about living with
migraine, overall 85% of respondents (88% of those
with ≥2 TFs) reported at least 1 negative aspect of liv-
ing with migraine. The most mentioned aspect was the
feeling of being misunderstood by people (48%),
followed by depression (41%) and feelings related to
hating their own life (39%), feeling helpless (39%), and
feeling that migraine controls and dictates their lives
(39%). An average of 27% of all respondents were ei-
ther very or extremely fearful of experiencing another
episode of migraine (average of 32% among those with
≥2 TFs). Despite all the negative aspects, 57% of re-
spondents mentioned at least 1 positive aspect of living
with migraine, mainly related to gaining resilience and
strength: ‘I have learnt to cope with the disease’ (40%),
‘I am responsible for my migraine’ (13%), and ‘It has
made me stronger’ (11%).
Impact on private, social, and professional life
Impact of migraine on professional, private, or social
domains was reported by 87% of respondents (51% in
all domains). Sixty-four percent of respondents re-
ported that migraine had affected their private life
(70% of respondents with ≥2 TFs), including relation-
ships with friends, relatives, and partners. On average
each respondent mentioned 4 negative impacts related
to missing important events (birthdays, weddings)Table 5 Functional and Emotional Impact of Migraine
Impact Total Populat
(n = 11,266)
Severity of pain (range from 0 to 10; mean reported) 7.4
Ever cancelled plans due to migraine 80% (9013)
Often or always feeling frustrated by migraine 56% (6309)
Migraine often or always interfering with ability to think
clearly or to focus on daily life activities and tasks
52% (5838)
Level of migraine interference with daily activities
(“a lot” or “constantly”)
51% (5746)
Often or always lacking the energy to complete daily living
or felt fatigued
50% (5633)
Level of impairment in daily activity due to migraine
(needing to stop and rest “a lot” or “always”)
45% (5070)
Often or always feeling hopeless or helpless by migraine 43% (4844)
TF Treatment failure(52%), avoiding making commitments (50%), effect on
sex life (49%), and feeling guilty about the impact mi-
graine has on their family life (44%).
Social activities were also affected for 78% of respon-
dents (82% in the ≥2 TFs subgroup). On average each
respondent mentioned 3 negative impacts with the
most mentioned being not participating in all activ-
ities/hobbies they used to (59%), being stopped from
going to social events (57%), and being stopped from
engaging in sports activities or exercise (34%).
Over the previous 3 months, 61% had relied on ex-
ternal support from family friends or someone else to
cope with daily tasks (64% in the ≥2 TFs subgroup). In
the 3 months before answering the survey, assistance
was required for 12.8 days on average for physical (eg,
cooking, cleaning, shopping), emotional (eg, support,
comfort, understanding), and medical (eg, taking/pro-
viding medication, transport to doctor, buying medica-
tion at pharmacy) aspects of life by 86%, 66%, and 49%
of respondents, respectively. In the same time period,
respondents with ≥2 TFs required more support (13.6
days on average), and 54% of respondents with ≥2 TFs
required help with medical aspects compared with 49%
of all respondents with migraine.
Impact of migraine on work productivity
Of all survey respondents, 70% reported that migraine
has affected their professional life, which rose to 75%
in the ≥2 TFs subgroup and was significantly higher
than those with no TF (60%) (P < 0.05). The top 3 im-
pacts of migraine on work reported by the respondents
were inability to concentrate on work (52%), missing
too many days of work (32%), and lack of understand-
ing among colleagues about their condition or taking it
seriously (27%). Out of the 58% of respondents who
were in full- or part-time paid employment, 63% re-
ported that their employers were aware of theirion Migraine Individuals
With 1 TF (n = 961)
Migraine Individuals
With ≥2 TFs (n = 6717)
P-value
(≥2 TFs vs 1 TF)
7.3 7.5 < 0.05
75% (721) 83% (5575) < 0.05
55% (529) 59% (3963) < 0.05
52% (500) 56% (3762) < 0.05
48% (461) 57% (3829) < 0.05
48% (461) 54% (3627) < 0.05
42% (404) 49% (3291) < 0.05
38% (365) 47% (3157) < 0.05
Table 6 Resource Utilization by Number of Previously Used
Migraine Preventive Treatments
Total Population
(n = 11,266)
Persons With
Migraine With
1 TF (n = 961)
Persons With
Migraine With
≥2 TFs (n = 6717)
Brain scan
Proportion of
respondents
58% (6534) 56% (538) 68% (4568)
Average number
of scans
2.1 1.7 2.3
ED visits in past 12 months
Proportion of
respondents
38% (4281) 28% (269) 46% (3090)
Average number
of visits
3.3 2.7 3.5
Overnight hospital stay in past 12 months
Proportion of
respondents
23% (2591) 15% (144) 29% (1948)
Average nights
of stay
3.2 2.3 3.4
ED Emergency department; TF Treatment failure
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18% reported receiving any support from their em-
ployer. Of all respondents, 9% (12% of those with ≥2
TFs) reported receiving a disability-related allowance
because of their migraine.
A majority of respondents in employment (60%) re-
ported missing ≥1 day of work in the last month due to
migraine, with an average of 4.6 working days being
missed in the last month, which is consistent with the
average of 4.5 working days missed due to migraine (ab-
senteeism) measured by the WPAI questionnaire. Notably,
the ≥2 TFs subgroup missed an average of 5 working days
due to migraine, which was significantly higher vs 3.8 days
missed by those with 1 TF (P < 0.05). However, paid sick
days reported by respondents in employment in the last
month were on average 2.4 days: 2.7 days in the ≥2 TFs
subgroup vs 1.7 days in those with 1 TF (P < 0.05).
Of the 7339 (65%) respondents who reported being
currently employed, 6606 reported having worked in
the last 7 days. These study participants reported that
migraine led to a reduction of 13% in their working
time (absenteeism) and 48% in productivity while
working (presenteeism); 52% reported impairment in
both overall work productivity (absenteeism and pres-
enteeism combined) and daily activities due to mi-
graine. Subgroup analysis according to prior treatment
failure showed that impairment in all WPAI scores
(absenteeism, presenteeism, and impairment in overall
work productivity and daily activities) was highest in
respondents with ≥2 TFs, followed by the 1 TF, no TF,
and treatment-naïve subgroups.
Healthcare resource utilization
In the previous 6months, the majority of respondents re-
ported visiting a general practitioner (GP) (53%), whereas
smaller but notable proportions also visited a neurologist
(40%), pharmacist (19%), headache specialist (15%), dentist
(12%), physiotherapist (11%), and psychologist or psych-
iatrist (10%). A majority of respondents (58%) reported
having had a brain scan (average of 2.1 scans); by compari-
son, 68% of respondents in the ≥2 TFs subgroup had
undergone an average of 2.3 brain scans over time
(Table 6), which was significantly higher than the 29% of
treatment-naïve respondents who had undergone an aver-
age of 1.7 brain scans (P < 0.05).
In the previous 12 months, more than a third of re-
spondents had visited the emergency department (ED)
because of their migraine and had on average 3.3 visits
in the last year, whereas nearly a quarter stayed in hos-
pital overnight (3.2 nights on average) (Table 6).
Discussion
This large worldwide study of 11,266 participants con-
stitutes the largest survey to date conducted inindividuals with migraine suffering from ≥4 MMDs
and focused mostly on those who previously experi-
enced failure of migraine prevention treatments. The
size and granularity of this study have created a rich
data source to describe the impact of migraine in this
economically active population, with personal, social,
and professional commitments and high healthcare use
in unprecedented detail.
The study data reveal that individuals with migraine,
especially those with a history of previous preventive
treatment failures, have higher levels of unmet needs.
This study describes the personal, social, humanistic,
and economic burden of migraine in detail, and for the
first time, it allows quantifying the burden during dif-
ferent phases of the migraine attack for individuals suf-
fering from ≥4 MMDs with a history of prophylactic
treatment. Although the headache phase itself caused
the highest degree of impairment, the findings demon-
strate that the burden of migraine extends beyond the
headache phase itself and is higher for individuals who
had at least one previous preventive treatment failure.
Respondents that had ≥4 MMDs reported a high rate
of ED visits and overnight stays in the hospital due to
migraine. Also, those with a history of failed preventive
treatments for migraine had even higher utilization of
healthcare resources. This trend suggests that treat-
ment failure in migraine may be an important driver of
increased healthcare utilization. These findings are
consistent with the results of the IBMS study, which
found that for each of the five European countries
studied, chronic migraine (per ICHD-2 criteria, per-
sons with ≥15 MMDs) was associated with additional
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medical services and associated cost [6]. However, un-
like the IBMS study, the My Migraine Voice partici-
pants cover a larger range of migraine individuals (≥4
MMDs), therefore providing a more comprehensive
appraisal of burden and healthcare utilization.
In addition to the direct economic burden, results of
this study highlight the substantial indirect economic
burden imposed by migraine. Loss in work productiv-
ity and activity impairment due to migraine is higher
in individuals with previously failed preventive treat-
ments, further establishing the need for more effective
treatment options in this particular population to en-
sure that these affected persons can fully contribute to
the productive workforce and society.
The present study has some limitations for consider-
ation. The recruitment of participants aimed to select
migraine individuals with ≥4 MMDs. While the sample
does not entirely mirror the overall general population
of people with migraine, it allowed selecting a repre-
sentative and generalizable sample of individuals with
severe disease. Recruitment bias may affect the esti-
mates where differences are present between survey
participants and the population from each country. For
example, individuals with 1 to 3 MMDs are not in-
cluded as part of this study, nor are people with mi-
graine without ready access to the internet or those
who are not part of the catchment group contacted to
participate in this survey. Pooling data from different
countries may also introduce some variability in the
dataset, unless country-specific nuances can be
accounted for. Another limitation of this study is the
use of self-reported data because diagnosis of migraine
and other relevant diagnoses (eg, those used in the co-
morbidity index) and reporting of healthcare visits and
other variables of interest cannot be clinically con-
firmed. However, there is no substantial reason why
one would not believe a self-reported migraine diagno-
sis if that individual can identify what type and when
the physician diagnosed him/her with migraine. The
magnitude of migraine impact is likely affected by the
frequency, severity, and duration of migraine, which
may also be susceptible to impact from reporting and
recall biases. Moreover, My Migraine Voice has been
completed and currently no follow-ups are planned.
Therefore, although it is the largest cross-sectional
study specifically reporting the burden of disease in
individuals with severe migraine to date, it does not
benefit from the additional insights that a longitudinal
study in the same population might reveal about the
time evolution of migraine and its multifaceted burden.
Despite the limitations above, this study strikes a
balance between the sample size needed to obtain a
higher-resolution description about the burden ofmigraine imposed on affected individuals with the
highest unmet need (≥4 MMDs) and potential caveats
in generalizing its findings to all people with migraine
(irrespective of disease severity) resulting from the
above-mentioned limitations. The impact of migraine
on the lives of affected individuals was also measured
by some patient-reported outcome measures. A web-
based approach appears to be an appropriate method
to capture cross-sectional or longitudinal data and
grants access to a population that would typically not
be found in clinical settings, allowing a determination
of the global burden of migraine [5, 13]. A follow-up
study, IBMS-II, was conducted [14] with the objective
to characterize patterns of preventive medication use
in persons with migraine; it concluded that persons ex-
periencing a higher frequency of migraine days tried
more medications than those with a lower number of
MMDs. My Migraine Voice adds to the existing litera-
ture since it includes a large number of countries, in-
volves people with migraine meeting the ICHD-3
criteria, and assesses migraine burden during premoni-
tory, headache, and postdrome phases of the migraine
attack, thereby allowing for a comprehensive and truly
global assessment of migraine burden.
Conclusions
This study demonstrates that the burden of migraine
is significant and poses several challenges among
those with ≥4 MMDs and a history of prophylactic
treatment failure. However, despite challenges posed
by migraine, only 9% reported receiving disability al-
lowance due to their migraine. Interestingly, the data
show that individuals with migraine report some posi-
tive aspects in their migraine journey, which relate to
developing a positive outlook on personal growth that
is likely triggered by learning to cope with the disease.
The greater resilience and strength brought on by
coping with migraine suggests that if future treat-
ments could address their existing unmet needs, these
individuals with migraine will be able to maximize
their contribution to society.
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